Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $20.28, for a total transaction of $152,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ DNLI opened at $20.01 on Friday. The business’s fifty day moving average price is $19.99. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $28.86. The company has a current ratio of 11.55, a quick ratio of 11.55 and a debt-to-equity ratio of 0.14.
Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. The firm had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $12.88 million. On average, research analysts anticipate that Denali Therapeutics Inc will post -1.54 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citigroup Inc. boosted its holdings in Denali Therapeutics by 594.7% during the fourth quarter. Citigroup Inc. now owns 89,314 shares of the company’s stock worth $1,845,000 after buying an additional 76,458 shares in the last quarter. Lord Abbett & CO. LLC boosted its holdings in Denali Therapeutics by 27.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,438,608 shares of the company’s stock worth $29,722,000 after buying an additional 313,153 shares in the last quarter. Rhumbline Advisers boosted its holdings in Denali Therapeutics by 59.6% during the fourth quarter. Rhumbline Advisers now owns 60,849 shares of the company’s stock worth $1,257,000 after buying an additional 22,712 shares in the last quarter. Northern Trust Corp boosted its holdings in Denali Therapeutics by 2.4% during the fourth quarter. Northern Trust Corp now owns 613,964 shares of the company’s stock worth $12,685,000 after buying an additional 14,105 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in Denali Therapeutics by 114.9% during the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock worth $924,000 after buying an additional 23,900 shares in the last quarter. 71.69% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently commented on DNLI shares. HC Wainwright reaffirmed a “buy” rating on shares of ACASTI PHARM-TS in a report on Wednesday, June 26th. ValuEngine raised shares of WPP from a “sell” rating to a “hold” rating in a report on Wednesday, June 19th. TheStreet raised shares of SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a report on Thursday, June 13th. Finally, Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Denali Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.50.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.